Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
about
Spinal cord injury neuroprotection and the promise of flexible adaptive clinical trialsA Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and EthicsAn integrative paradigm to impart quality to correlative science.Rethinking Phase II Clinical Trial Design in Heart Failure.Outcome--adaptive randomization: is it useful?Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trialsRandomized phase II trials: a long-term investment with promising returnsInforming sequential clinical decision-making through reinforcement learning: an empirical study.Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire ResponsesA comparison of two worlds: How does Bayes hold up to the status quo for the analysis of clinical trials?Evaluation of vaccine seroresponse rates and adverse event rates through Bayesian and frequentist methods.Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial.Bayesian adaptive randomized trial design for patients with recurrent glioblastomaBayesian clinical trials in actionAn overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) projectBayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Bayesian adaptive randomization designs for targeted agent development.Biomarkers in T cell therapy clinical trials.Adaptive clinical trials in oncology.Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma.Adaptive designs for dual-agent phase I dose-escalation studies.Practical characteristics of adaptive design in phase 2 and 3 clinical trials.Emerging innovations in clinical trial design.Bayesian survival analysis in clinical trials: What methods are used in practice?Bayesian adaptive clinical trials: a dream for statisticians only?Isolated limb perfusion for unresectable extremity sarcoma: results of 2 single-institution phase 2 trials.Use of Bayesian statistics in drug development: Advantages and challenges.Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.Are outcome-adaptive allocation trials ethical?The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs.Bayesian statistics in medical devices: innovation sparked by the FDA.A decade of Clinical Trials.Designing a series of decision-theoretic phase II trials in a small population.A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.Biomarker-led adaptive trial blazes a trail in breast cancer.Bayesian clinical trials: no more excuses.Bayes and MCMC for Undergraduates
P2860
Q27008862-4CDEA9A8-4404-4320-9854-5A50A42D29BDQ30977270-5987353E-922C-49F9-8242-B0143621AEA8Q33765942-FCE48962-655E-4574-9A63-14001597B900Q34377514-A90BF3C0-9CFF-4C74-9D05-96B36E832A6EQ34667846-A26173D0-DAB9-45EE-A5E4-75B28920BA32Q35041013-8E6C1744-3740-4FC2-8254-0D2EB67AE3EBQ35115259-5B8A7F36-EF37-4B1A-8A25-288CBF547E8BQ35127824-B4BC8093-C16F-46F3-8224-662734AD92FDQ35687969-7EEB03DF-2F29-44E9-AE31-269DF6585221Q35771013-32CA78F5-830E-41B0-BB7D-A94A12B51E6BQ35887727-08854ECE-6E06-48AE-A729-48E6D96D698FQ36158310-1C88FB47-66A7-46A6-AB37-294806AE572EQ36212432-53CC356C-D8E1-46BD-8D24-CEA4EB6101A7Q36392556-98F6D1AD-41DF-440B-B3EB-14577E98E4CCQ36570348-54FD35E4-4E48-442F-87E4-AFE6EC2764B1Q37238720-4B7B8725-4C22-489A-8BF4-AC9A288FA42AQ37415504-0BA21171-BB0A-45C8-A3F6-394B0977B06BQ37919589-1ED3E17C-0306-44C1-8CB4-3C965328B954Q37953783-BAD3EF5B-F0A6-4475-8C56-F79340630179Q38041058-03069F4A-97D3-475D-9540-37735820B552Q38090897-F365CC29-7862-4F63-BF35-D8AEA147714FQ38603746-E7FD3062-CD7C-43B8-B69F-F67B314BB8F1Q38631473-903B8F1A-E5B1-47A9-B0F6-109DA908ADDDQ38978314-9D6511B0-AA69-4E99-838E-A9EECCCAAA22Q39709250-9931926E-E698-4049-9AD4-EE8DAF6A62C5Q39792461-6C420910-BA5A-4A71-8524-C9C139284A04Q40828042-62150B48-13C2-4027-9D98-DBEDCF5FB39CQ41498775-CCFA4994-1B65-435D-AD64-2283A974B4F4Q41677600-3D117694-D027-47CF-9C9D-49B8F65233BCQ42359019-1A669220-C89B-4256-AA1D-3E993E5AED39Q45745710-F5761CFD-EB78-475A-928F-73C86DF54B81Q46750545-D00DB10E-D40A-421C-8D92-3BB553394AFCQ47215345-6D33BA26-5665-4AC1-9A1D-E6726D97A612Q47297087-59CAAB02-CE6B-46F6-A390-0E0790295104Q51698791-7C2E9B93-7FD8-4436-8B88-C623F5E42A20Q51820132-66A17A25-2526-4B6E-9EBC-1FC2FE20CE22Q58262328-AA384474-4C8C-4E7C-9DC6-2D2FFA901D4A
P2860
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@ast
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@en
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@nl
type
label
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@ast
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@en
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@nl
prefLabel
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@ast
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@en
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@nl
P2093
P2860
P356
P1433
P1476
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
@en
P2093
Diane D Liu
Donald A Berry
J Jack Lee
Swati Biswas
P2860
P304
P356
10.1177/1740774509104992
P577
2009-06-01T00:00:00Z